v3.26.1
ACQUISITION (Notes)
 9 Months Ended
Jul. 31, 2026
Business Combination [Abstract]  
Acquisition ACQUISITION
Acquisition of Biocare

On June 24, 2026, we acquired 100 percent of the outstanding capital stock of BC Midco I, Inc. ("Biocare") for a net consideration paid of $950 million. Biocare is a leading provider of clinical and research solutions and is included within our Life Sciences and Diagnostics Markets segment. The acquisition of Biocare expands our pathology portfolio enabling us to better serve our pathology customers across clinical and research settings. As a result of the acquisition, Biocare became a wholly-owned subsidiary of Agilent. Accordingly, the results of Biocare are included in Agilent's condensed consolidated financial statements from the acquisition date.

The Biocare acquisition was accounted for in accordance with the authoritative accounting guidance for business combinations. The acquired assets and assumed liabilities were recorded at their estimated fair values. We determined the estimated fair values with the assistance of valuations performed by a third-party specialist, discounted cash flow analyses and estimates made by management. We expect to realize revenue synergies, expand the existing sales channels and product development resources, and benefit from the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of Biocare’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction. All goodwill acquired was allocated to the Life Sciences and Diagnostics Markets operating segment and reporting unit as part of the purchase price allocation.

Our acquisition of Biocare is treated as a stock acquisition and therefore is not deductible for United States federal tax purposes.
The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of June 24, 2026 (in millions):

Purchase Price
Cash paid$964 
Less: Cash acquired(14)
Net cash consideration$950 
Net assets acquired
Current assets27 
Property, plant and equipment8 
Goodwill549 
Other intangible assets:
Customer relationships372 
Developed technology145 
Trade names3 
Other assets6 
Liabilities assumed(59)
Deferred tax liability(101)
Total net assets acquired$950 

Other identifiable intangible assets consist of customer relationships, developed technology, and trade names. These finite-lived intangible assets have estimated useful lives of 15 years for customer relationships and developed technology and 3 years for trade names, resulting in a weighted-average estimated useful life of approximately 15 years.

Supplemental pro forma revenue and net income have not been presented because the effects of the acquisition were not material to our condensed consolidated financial statements.